Anti-VEGF therapies represent the largest drug segment in the Intravitreal Injection Market, reflecting their role as standard of care for major retinal diseases. Vascular endothelial growth factor (VEGF) drives abnormal blood vessel growth and leakage in conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Anti-VEGF injections—including ranibizumab, aflibercept, and bevacizumab—block VEGF activity, reducing leakage and preserving vision. Their efficacy has transformed retinal disease treatment and driven market growth.

The Intravitreal Injection Market reflects anti-VEGF dominance. These therapies are used in millions of injections annually worldwide. Ranibizumab and aflibercept are widely used, while bevacizumab is used off-label in many regions due to lower cost. Newer therapies—including faricimab and brolucizumab—offer longer dosing intervals, reducing treatment burden for patients and providers.

Corticosteroids represent a smaller but important segment, used for DME and uveitis. Sustained-release implants offer long-acting options. Biosimilars are emerging, potentially improving access by reducing costs. As the retinal disease burden grows and as new therapies are approved, anti-VEGF therapies are expected to remain the dominant segment driving growth in the Intravitreal Injection Market.

People Also Ask

• What are anti-VEGF injections?
  Anti-VEGF injections block vascular endothelial growth factor, reducing abnormal blood vessel growth and leakage in retinal diseases like AMD and DME.

• How often are intravitreal injections needed?
  Frequency varies by drug and condition, ranging from monthly to every few months. Longer-acting therapies are reducing injection frequency.

Tags: #AntiVEGF #IntravitrealInjection #AMD #DME #RetinalDisease #Ophthalmology